First Hospital Jilin University
Changchun, Jilin, 130061, China
NCT Number: NCT04593355
The purpose of this study is to determine whether the morbidity of hepatitis C with Chinese population.
Looking for future studies?
Notify Me20 year–85 year
All sexes
Observational
Changchun, Jilin, 130061, China
Hepatitis C virus (HCV) infection rate in China is about 3%, which means about 30 million patients. More importantly, many of those patients with chronic hepatitis C eventually develop cirrhosis and hepatocellular carcinoma(HCC).Our survey found the rate of hepatitis c infection in northeastern China without intervention is 34.3%, due to the abuse of caffeine sodium benzoate. This population has the similar mode of transmission, which is a fine study of the natural outcome hepatitis C. We plan to carry out epidemiological studies for this population, review of the influencing factors of the disease, and analyze the host factors that can effect the prognosis.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: Baseline
Co-infection status are analyzed.
Time frame: Baseline
ALT AST are assayed to detect the hepatic function.
Time frame: Baseline
Fibrosis is analyzed with Fibroscan.
Time frame: Baseline
The distribution and absolute count of the different types of blood cells are assayed.
Time frame: Baseline
Blood HCV RNA copies were assayed with Roche - COBAS® AmpliPrep/COBAS® TaqMan® HCV Test.
Time frame: Baseline
HCV NS5A is cloned into T vector and sequenced for evolutionary analysis.
Time frame: Baseline
Patients will be asked about their drug usage history.
Time frame: Baseline
Patients are asked whether they take alcohol or smoke cigarettes during the therapy period.
The First Hospital of Jilin University
Other
HCV Epidemiological Survey of Chinese in Northeast Rural Area Which Have Injection History
Acronym: HCVES
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT00901524
Blood-Borne Infections, Communicable Diseases
Paris, France
View Trial DetailsNCT02103439
Blood-Borne Infections, Communicable Diseases
Kazan', Tatarstan Republic, Russia
View Trial DetailsNCT01889433
Blood-Borne Infections, Communicable Diseases
Homyel, Belarus
View Trial DetailsNCT03482388
Behavior, Blood-Borne Infections
Guangzhou, China
View Trial Details